Tech Company Financing Transactions
Aeglea BioTherapeutics Funding Round
Aeglea BioTherapeutics, operating out of Austin, secured $12 million in investment from KBI Biopharma.
Transaction Overview
Company Name
Announced On
1/9/2014
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Undisclosed
Investors
Proceeds Purpose
During the next 15 to 18 months, the company plans to begin manufacturing of its lead molecule and complete the prep work to begin the first phase of clinical trials.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
901 S. MoPac Expy. Barton Oaks Plz. One 250
Austin, TX 78746
USA
Austin, TX 78746
USA
Phone
Website
Email Address
Overview
Aeglea BioTherapeutics (NASDAQ: AGLE) is developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony Quinn
Chief Financial Officer
Charles York
Chief Medical Officer
James Wooldridge
Chief Operating Officer
Leslie Sloan
VP - R & D
Scott Rowlinson
Browse more venture capital transactions:
Prev: 1/9/2014: Immedia Semiconductor venture capital transaction
Next: 1/9/2014: Vobile venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs